MaxCyte Inc (NASDAQ:MXCT) — Market Cap & Net Worth
Market Cap & Net Worth: MaxCyte Inc (MXCT)
MaxCyte Inc (NASDAQ:MXCT) has a market capitalization of $84.42 Million ($84.42 Million) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #19719 globally and #4456 in its home market, demonstrating a -6.25% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying MaxCyte Inc's stock price $1.05 by its total outstanding shares 106674011 (106.67 Million). See MXCT capex to operating cash flow ratio to understand how much of operating cash flow is reinvested back into capital assets.
MaxCyte Inc Market Cap History: 2021 to 2026
MaxCyte Inc's market capitalization history from 2021 to 2026. Data shows change from $1.09 Billion to $112.01 Million (-42.67% CAGR).
Index Memberships
MaxCyte Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.00% | #559 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #1904 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.72 Trillion | 0.00% | #243 of 263 |
Weight: MaxCyte Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
MaxCyte Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how MaxCyte Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
11.49x
MaxCyte Inc's market cap is 11.49 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.09 Billion | $33.89 Million | -$19.08 Million | 32.07x | N/A |
| 2022 | $582.44 Million | $44.26 Million | -$23.57 Million | 13.16x | N/A |
| 2023 | $501.37 Million | $41.29 Million | -$37.92 Million | 12.14x | N/A |
| 2024 | $443.76 Million | $38.63 Million | -$41.05 Million | 11.49x | N/A |
Competitor Companies of MXCT by Market Capitalization
Companies near MaxCyte Inc in the global market cap rankings as of August 3, 2026.
Key companies related to MaxCyte Inc by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #114 globally with a market cap of $183.80 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #189 globally with a market cap of $124.64 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #233 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #238 globally with a market cap of $103.60 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #114 | Abbott Laboratories | NYSE:ABT | $183.80 Billion | $105.70 |
| #189 | Stryker Corporation | NYSE:SYK | $124.64 Billion | $325.70 |
| #233 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #238 | Medtronic PLC | NYSE:MDT | $103.60 Billion | $85.39 |
MaxCyte Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, MaxCyte Inc's market cap moved from $1.09 Billion to $ 112.01 Million, with a yearly change of -42.67%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $112.01 Million | -32.26% |
| 2025 | $165.34 Million | -62.74% |
| 2024 | $443.76 Million | -11.49% |
| 2023 | $501.37 Million | -13.92% |
| 2022 | $582.44 Million | -46.42% |
| 2021 | $1.09 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of MaxCyte Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $84.42 Million USD |
| MoneyControl | $84.42 Million USD |
| MarketWatch | $84.42 Million USD |
| marketcap.company | $84.42 Million USD |
| Reuters | $84.42 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About MaxCyte Inc
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based … Read more